Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity

ABSTRACT Immunotherapy has significantly improved treatment outcomes for cancer patients within the past decade, with breakthrough results using immune checkpoint inhibitors (ICIs), most notably those targeting the PD‐1/PD‐L1 inhibitory axis. Nevertheless, many patients and tumor types do not respon...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Lisa J. Jacob, Liat Tamir, Mufeed Abdeen, Ami Tamir, Alexandra Aronin, Itai Bloch, Roy Kahn, Iris Pecker, Mark Tykocinski, Gerwin Huls, Yaron Pereg, Ayelet Chajut, Edwin Bremer
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2026-06-01
Цуврал:	Advanced Science
Нөхцлүүд:	CD47 HLA‐G immune checkpoints immunotherapy LILRB1 LILRB2
Онлайн хандалт:	https://doi.org/10.1002/advs.202521448
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!